INTRODUCTION
A high level of case ascertainment by cancer registries is essential to allow estimation of accurate incidence rates and survival. Nearly 20 years ago, researchers assessed the completeness and accuracy of registration of primary intracranial tumours in the Scottish Cancer Registry (SCR) 1 compared to a database assembled in the context of a detailed incidence study carried out in the Lothian region of Scotland covering the period of diagnosis, 1989-1990 [1] [2] . Disappointingly, SCR identified only 54% of cases, although the registry at that time did not attempt to collect information on 'benign' intracranial neoplasms which were included in the detailed incidence study. Even so, only 84% of neuro-epithelial tumours were identified by SCR, probably related in part to the fact that, the cancer registry was not receiving neuropathology data from the regional neuro-oncology
centre. An English study reported similar findings with only 52% of cases appearing in the regional cancer registry 3 .
Over time, access to diagnostic techniques has improved alongside improvements and changes in classification and clinical coding. Furthermore, SCR now receives neuropathology data from all neuro-oncology centres in Scotland, and has sought to collect information on benign tumours of the brain and spinal cord since the year of diagnosis, 2000. In light of these developments, we aimed to determine the completeness of ascertainment of primary intracranial tumours by SCR through independent/clinical case ascertainment in NHS Lothian for the period of diagnosis, 2011-2012.
METHODS

Scottish Cancer Registry (SCR)
SCR operates by bringing together predominantly electronic information from: hospital patient administration systems including patient discharges from hospital (SMR01), radiotherapy, oncology, pathology records; death records from National Records Scotland (NRS); and private hospital records 4 . All primary malignant and benign brain tumours are recorded on the SCR.
Inclusion and exclusion criteria
This retrospective cohort study was restricted to the period of diagnosis between 1/1/11 and 31/12/12 and limited to adults (age ≥18years on the date of diagnosis) with a postcode within the NHS Lothian health board region (mid-year population ~650,000). The date of diagnosis was taken as i) the date of the first abnormal imaging, or ii) the date of biopsy/resection. Patients in whom there was no neuro-radiology or histology were excluded, i.e. diagnosis of prolactinoma had to be supported by blood tests and imaging.
All suspected and histologically proven primary intracranial tumours (benign and malignant) of the brain and cranial nerves were counted, including primary central nervous system lymphoma. 
Clinical case ascertainment
Three clinical sources were trawled: i) neuro-oncology multidisciplinary meeting minutes (MTDM); ii) an endocrinology database; and iii) neuropathology records (sources i and ii are independent of the SCR data collection system). The neuro-oncology MDTM aims to discuss all intracranial tumours identified via any means including both benign and malignant tumours. The endocrinology database records all patients attending the endocrine outpatient clinics in the NHS Lothian region and each is assigned a diagnosis by a Consultant Endocrinologist. Both sources i and ii for the period 1 Jan 2011 to 31 March 2013 were reviewed manually by JRM. The neuropathology records hold information on all tissue samples analysed in the pathology system for NHS Lothian hospitals and an electronic extract was obtained using Systematized Nomenclature of Medicine (SNOMED) codes matching those above. To ensure cases were true incident cases meeting the full inclusion criteria, each was cross referenced with the patient's electronic secondary care medical record.
Analysis
Clinically ascertained cases were reconciled against the SCR extract. We have previously quantified the extent of misclassification of incidence year in the Scottish Cancer Registration database 5 . We did not regard misclassifications of incidence year as missed or 'over-diagnosed' cases as there is no reason to believe that such misclassification is other than random.
Completeness was defined as the proportion of intracranial tumours included in the SCR out of all those identified as diagnosed in residents of NHS Lothian area during the study period. Confidence intervals (95%) for completeness were calculated using the exact method.
Completeness was calculated for all intracranial tumours with secondary analysis of completeness by tumour morphology and tumour grade (see Supplementary File for coding definitions).
Ethical approval
The study was considered health-service audit and did not require NHS ethical review as the project was limited to the utilisation of data previously collected in the course of normal care. NHS Lothian Caldicott Guardian approval was obtained for the use of person-identifiable information.
RESULTS
There were 320 records of primary intracranial tumours registered on the SCR for the period of interest and 264 clinical cases were ascertained. Figure 1 shows the final ascertainment of clinical cases missing from the SCR.
42 clinical cases were identified as missing from the SCR, with 98 cases on the SCR not identified by searching clinical sources. The 42 missing cases were identified from: neuro-oncology MDTM (7), endocrinology out-patient database (30) and neuropathology records (5).
Overall case ascertainment was 88.4%, which after exclusion of pituitary adenomas (22.6% macroand 77.4% micro-adenomas) rose to 96.3% Table 1 shows the ascertainment by tumour morphology. All tumour types had ascertainment >90% with the exception of pituitary adenomas (53.7%) and unidentifiable tumours (77.8%). Considering tumours by grade (with pituitary adenomas removed due to poor acquisition), missing cases were most prominent in the high grade (IV) tumours, with 4.8% of cases missing.
Of the 98 cases on the SCR not identified in the clinical case ascertainment the reasons for nonascertainment were: 7 (7.1%) died within 1-month of the diagnosis or were registered from death certification/autopsy, 9 (9.2%) had a diagnostic date recorded in their medical records outside of the period 2011-12, 79 (80.6%) were confirmed as accurate registrations from their medical records but were not referred to the neuro-oncology MDTM or had pathology specimens taken, and 3 (3.1%) were diagnosed and/or treated outside of the NHS Lothian region.
The morphology of these 98 were: 9 (9.2%) neuroepithelial, 19 (19.4%) cranial nerve, 49 (50.0%) meningeal, 1 (1.0%) primary CNS lymphoma, 11 (11.2%) pituitary adenomas, and 9 (9.2%) unknown.
DISCUSSION
This study found the SCR to be near complete (96.3%) for non-pituitary intracranial tumours. This finding is reassuring given the increasing reliance on routine data sources in clinical research in the 'big data' era.
A key strength of this work was the use of predominantly independent clinical case ascertainment.
Two of the three sources used were independent of the SCR with the pathology database part of the routine reporting system. Use of dependent sources would lean to an over-estimation of the completeness, however, we are confident in our finding as the search employed for the pathology extract was more extensive than the SCR compiling extract and we did identify further missing cases.
To further augment the clinical case ascertainment imaging sources could also be used.
Unfortunately it was not possible for us to do this due to the very high volume of imaging activity and the fact that report findings are not synoptic or coded.
Another possible weakness was the use of a single researcher (JRM) in identifying independent cases. To try and minimise missing cases or misclassification, all missing cases had the medical records rechecked by the researcher and a member of the SCR data quality assurance team reviewed the registry for the entry, outside of the extract requested.
This work replaces prior completeness estimates published in the late 1990's 1 and shows a clear improvement in the completeness of ascertainment. This is likely to relate to operational changes in the way that data are collected by SCR and the decision to collect data on benign brain tumours from year 2000 onwards. It is possible that completeness of ascertainment of tumours varies by site with other cancers potentially having higher completeness, however these findings are more consistent with estimates of completeness of ascertainment for other cancer sites/types in SCR [6] [7] .
It is important that outdated estimations of completeness of ascertainment of intracranial tumours are revised to ensure robust estimates of intracranial tumour incidence are made and understood.
The use of outdated information can lead to misleading inferences, for example, The Brain Tumour
Charity continues to report a belief that "many brain tumours are not recorded" in official statistics in Scotland 8 .
Conclusion
Given the increase in intracranial tumours being diagnosed by imaging we would recommend a move towards diagnostic coding of imaging in Scotland. A further issue to address in the future relates to the recording of benign pituitary tumours -predominantly microadenomas. We found that most of these were noted in the records of out-patient endocrinology attendances following CT/MRI scanning. It is unclear how a national system to collect these could be implemented because, at present, diagnosis is not coded in either computerised imaging data or outpatient data collected routinely.
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